Open AccessPersonalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab
Author(s) -
Laura Bergantini,
Miriana d’Alessandro,
Paolo Cameli,
Francesco Bianchi,
Piersante Sestini,
Elena Bargagli,
Rosa Metella Refini
Publication year - 2020
Publication title -
international archives of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.696
H-Index - 100
eISSN - 1423-0097
pISSN - 1018-2438
DOI - 10.1159/000508936
Subject(s) - medicine , mepolizumab , benralizumab , asthma , cohort , immunology , eosinophil , vital capacity , gastroenterology , lung , diffusing capacity , lung function
New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom